A Phase 1, Double-Masked, Placebo-Controlled, Dose Escalating Study of the Safety, Tolerability, and Pharmacokinetics of EBI-005 Topically Administered to Eyes of Healthy Adult Subjects

Trial Profile

A Phase 1, Double-Masked, Placebo-Controlled, Dose Escalating Study of the Safety, Tolerability, and Pharmacokinetics of EBI-005 Topically Administered to Eyes of Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Apr 2015

At a glance

  • Drugs Isunakinra (Primary)
  • Indications Allergic conjunctivitis; Dry eyes
  • Focus Adverse reactions
  • Sponsors Eleven Biotherapeutics
  • Most Recent Events

    • 27 Apr 2015 Results presented at the Association for Research in Vision and Ophthalmology (ARVO) 2015 Annual Meeting, as per Eleven Biotherapeutics media release.
    • 20 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top